Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 6, 2012, Pages 1445-1452

  Hadri, Khadija El ^a   Dler Faieeq Darweesh, Mahmood ^a   Couchie, Dominique ^a   Jguirim Souissi, Imene ^a   Genze, Felicitas ^b   Diderot, Vimala ^a   Syrovets, Tatiana ^b   Lunov, Oleg ^b   Simmet, Thomas ^b   Rouis, Mustapha ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Atherosclerosis; Inflammation; Macrophage; Thioredoxin 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; REDOX EFFECTOR FACTOR 1; THIOREDOXIN 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA INJURY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOWN REGULATION; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; IN VITRO STUDY; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTIC DISEASES; APOLIPOPROTEIN E2; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HUMANS; INFLAMMATION MEDIATORS; LECTINS, C-TYPE; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PHENOTYPE; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; THIOREDOXINS; TIME FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 84861527254     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.249334     Document Type: Article

References (56)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-184.
3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
4. Gordon S. The macrophage: past, present and future. Eur J Immunol. 2007;37 Suppl 1:S9-17.
5. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287-292.
6. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965-975.
7. Bouhlel MA, Derudas B, Rigamonti E, Diévart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6:137-143.
8. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010;285:6153-6160.
9. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, Gupta M, Chan L, Al-Omran M, Teoh H, Verma S. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol. 2010;299:H656-H663.
10. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-349.
11. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
12. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res. 2003;93:1029-1033.
13. Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102-6109.
14. Lillig CH, Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal. 2007;9:25-47.
15. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun. 2010;396:120-124.
16. Chae HZ, Chung SJ, Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem. 1994;269:27670-27678.
17. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem. 1998;273:6297-6302.
18. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237-271.
19. Tanaka T, Nakamura H, Nishiyama A, Hosoi F, Masutani H, Wada H, Yodoi J. Redox regulation by thioredoxin superfamily; protection against oxidative stress and aging. Free Radic Res. 2000;33:851-855.
20. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol. 1997;15:351-369.
21. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, Tanaka H. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest. 1996;98:2469-2477.
22. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem. 1999;274:3182-3188.
23. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606.
24. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys. 2004;429:123-133.
25. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999;274: 21645-21650.
26. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol. 2000;164:6287-6295.
27. Kondo N, Ishii Y, Kwon YW, Tanito M, Horita H, Nishinaka Y, Nakamura H, Yodoi J. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol. 2004;172:442-448.
28. Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem. 1992;267:24161-24164.
29. Wollman EE, d'Auriol L, Rimsky L, Shaw A, Jacquot JP, Wingfield P, Graber P, Dessarps F, Robin P, Galibert F. Cloning and expression of a cDNA for human thioredoxin. J Biol Chem. 1988;263: 15506-15512.
30. World C, Spindel ON, Berk BC. Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-a: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol. 2011;31:1890-1897.
31. Pekkari K, Avila-Cariño J, Bengtsson A, Gurunath R, Scheynius A, Holmgren A. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood. 2001;97:3184-3190.
32. Rosen A, Lundman P, Carlsson M, Bhavani K, Srinivasa BR, Kjellström G, Nilsson K, Holmgren A. A CD41 T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol. 1995;7:625-633.
33. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 1989;8:757-764.
34. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, Tursz T. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I-and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA. 1990;87: 8282-8286.
35. Billiet L, Furman C, Larigauderie G, Copin C, Brand K, Fruchart JC, Rouis M. Extracellular human thioredoxin-1 inhibits lipopolysaccharideinduced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem. 2005;280:40310-40318.
36. Dai J, Wang X, Feng J, Kong W, Xu Q, Shen X, Wang X. Regulatory role of thioredoxin in homocysteine-induced monocyte chemoattractant protein-1 secretion in monocytes/macrophages. FEBS Lett. 2008;582: 3893-3898.
37. Zeng X, Dai J, Remick DG, Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res. 2003;93:311-320.
38. Pagliei S, Ghezzi P, Bizzarri C, Sabbatini V, Frascaroli G, Sozzani S, Caselli G, Bertini R. Thioredoxin specifically cross-desensitizes monocytes to MCP-1. Eur Cytokine Netw. 2002;13:261-267.
39. Son A, Kato N, Horibe T, Matsuo Y, Mochizuki M, Mitsui A, Kawakami K, Nakamura H, Yodoi J. Direct association of thioredoxin-1 (TRX) with macrophage migration inhibitory factor (MIF): regulatory role of TRX on MIF internalization and signaling. Antioxid Redox Signal. 2009;11:2595-2605.
40. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol. 1999;10:151-159.
41. Mitsui A, Hamuro J, Nakamura H, Kondo N, Hirabayashi Y, Ishizaki-Koizumi S, Hirakawa T, Inoue T, Yodoi J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal. 2002;4:693-696.
42. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998;102:130-135.
43. Cuaz-Pérolin C, Billiet L, BaugéE, Copin C, Scott-Algara D, Genze F, Büchele B, Syrovets T, Simmet T, Rouis M. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2008;28:272-277.
44. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett. 2002;519:23-29.
45. Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K, Bouchaert E, Vanhoutte J, Fleury S, Remy P, Tailleux A, Chinetti-Gbaguidi G, Dombrowicz D, Staels B, Paumelle R. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood. 2011;118:2556-2566.
46. Chen B, Guan D, Cui ZJ, Wang X, Shen X. Thioredoxin 1 downregulates MCP-1 secretion and expression in human endothelial cells by suppressing nuclear translocation of activator protein 1 and redox factor-1. Am J Physiol, Cell Physiol. 2010;298:C1170-C1179.
47. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23:344-346.
48. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29:1419-1423.
49. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89:557-563.
50. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARg and LXRa pathways. Circ Res. 2011;108:985-995.
51. Fok WCY, Cortez L, Webb CR, Garcia N, Jones D, Yodoi J, A.G. R, Y. I, V.I. P. Overexpression of thioredoxin 1 in mice induced changes in NFkB and Nrf2 redox-sensitive signaling pathways. Society for Free Radical Biology and Medicine (SFRBM) 15th Annual Meeting, November 19-23, 2008, Indianapolis, Indiana. Abstracts. Free Radic Biol Med. 2008;45 Suppl 1:S13-167.
52. Lunov O, Syrovets T, Loos C, Nienhaus GU, Mailänder V, Landfester K, Rouis M, Simmet T. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano. 2011;5:9648-9657.
53. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327:296-300.
54. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
55. Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fruchart JC, Brand K, Rouis M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J Cell Physiol. 2008;214:183-191.
56. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, Herzenberg LA, Yodoi J. Circulating thioredoxin suppresses lipopolysaccharide- induced neutrophil chemotaxis. Proc Natl Acad Sci USA. 2001;98:15143-15148.